Table 2 Mendelian randomisation analyses of the association of RHOD and CDC42 with overall, ER+ and ER− breast cancer risk.
From: Rho GTPase gene expression and breast cancer risk: a Mendelian randomization analysis
Outcome | Exposure (gene expression level) | Tissue (data source) | MR method | nsnp | OR | LCI | UCI | P-value |
|---|---|---|---|---|---|---|---|---|
Overall breast cancer | RHOD | Breast mammary (GTEx) | Wald ratio | 1 | 1.06 | 1.03 | 1.09 | 5.65 × 10–5 |
ER+ breast cancer | RHOD | Breast mammary (GTEx) | Wald ratio | 1 | 1.08 | 1.05 | 1.12 | 2.29 × 10–5 |
ER− breast cancer | RHOD | Breast mammary (GTEx) | Wald ratio | 1 | 1.06 | 1.01 | 1.12 | 0.03 |
Overall breast cancer | RHOD | Blood (eqtlGen) | Wald ratio | 1 | 1.22 | 1.11 | 1.35 | 5.22 × 10–5 |
ER+ breast cancer | RHOD | Blood (eqtlGen) | Wald ratio | 1 | 1.32 | 1.18 | 1.49 | 2.74 × 10–6 |
ER− breast cancer | RHOD | Blood (eqtlGen) | Wald ratio | 1 | 1.19 | 0.99 | 1.42 | 0.06 |
Overall breast cancer | CDC42 | Breast cancer (TCGA) | Wald ratio | 1 | 0.91 | 0.84 | 0.98 | 0.02 |
ER+ breast cancer | CDC42 | Breast cancer (TCGA) | Wald ratio | 1 | 0.90 | 0.82 | 0.99 | 0.03 |
ER− breast cancer | CDC42 | Breast cancer (TCGA) | Wald ratio | 1 | 0.88 | 0.76 | 1.02 | 0.09 |
Overall breast cancer | CDC42 | Blood (eqtlGen) | Wald ratio | 1 | 0.96 | 0.93 | 1.00 | 0.03 |
ER+ breast cancer | CDC42 | Blood (eqtlGen) | Wald ratio | 1 | 0.95 | 0.91 | 0.98 | 0.005 |
ER− breast cancer | CDC42 | Blood (eqtlGen) | Wald ratio | 1 | 1.01 | 0.95 | 1.07 | 0.78 |
